Please ensure Javascript is enabled for purposes of website accessibility

Why MyoKardia Stock Is on Fire Today

By George Budwell – Updated May 11, 2020 at 10:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's experimental heart drug hit the mark in a pivotal study.

What happened

MyoKardia (MYOK), a clinical-stage biotech, is having a tremendous Monday morning. The drugmaker's shares were up by an eye-popping 65% on sky-high volume as of 9:59 a.m. EDT on Monday. 

The spark? Ahead of the opening bell, MyoKardia announced that its experimental obstructive hypertrophic cardiomyopathy drug mavacamten met all of its primary and secondary endpoints in a late-stage trial. Equally as important, mavacamten was also reportedly well tolerated in the study.

An excited kid staring at a tablet.

Image source: Getty Images.

Obstructive hypertrophic cardiomyopathy is a genetically based disorder characterized by abnormal thickening of the heart muscle, which can make it harder for the heart to pump blood. If approved, mavacamten has the potential to be a game-changer for this life-threatening heart disorder.  

So what

The big deal is that Wall Street thinks mavacamten could haul in peak sales in the neighborhood of $1.5 billion. That's a rather tidy sum for a company that started today's trading session with a market cap of less than $3 billion.

What's more, MyoKardia is probably now a top takeover candidate with a potential blockbuster heart medication in hand. Cardiovascular drugs tend to have exceedingly long commercial shelf lives, and several big pharmas have a keen interest in this particular market.    

Now what

Management said in the accompanying press release that it plans to file for the drug's approval with the Food and Drug Administration in the first quarter of 2021. If everything goes according to plan, mavacamten could be on the market as soon as the fourth quarter of next year. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MyoKardia, Inc. Stock Quote
MyoKardia, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.